OncLive TV

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.

Jeffrey S. Weber, MD, PhD, discusses research efforts examining neoadjuvant approaches in melanoma.

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.

Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Stuart L. Goldberg, MD, discusses financial toxicities faced in hematology.

Angela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.

Alexandra Sokolova, MD, discusses the systematic implementation of a germline testing protocol for patients with metastatic prostate cancer.

Brian T. Hill, MD, PhD, discusses the FDA approval of selinexor (Xpovio) in diffuse large B-cell lymphoma (DLBCL).

Michael Wang, MD, discusses the objectives of a comparative analysis of the phase 2 ZUMA-2 trial with KTE-X19 in patients with mantle cell lymphoma.

Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.

​Neal D. Shore, MD, FACS, discusses the rationale for conducting the phase 3 HERO trial in advanced prostate cancer.

Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.

Jüergen Wolf, MD, discusses the design and rationale of the phase 2 GEOMETRY mono-1 study with capmatinib (Tabrecta) in METex14-mutated or high MET amplified, advanced non–small cell lung cancer.

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

Chetasi Talati, MD, discusses the rationale for investigating venetoclax in acute myeloid leukemia.

Alexandra Sokolova, MD, discusses the rationale for systematic implementation of germline testing for patients with metastatic prostate cancer.

Meletios A. Dimopoulos, MD, discusses the utility of zanubrutinib (Brukinsa) in Waldenström macroglobulinemia.

Michael J. Morris, MD, discusses factors to consider when deciding among PET tracers in prostate cancer.

William K. Kelly, DO, discusses the design of a phase 1B dose-finding trial that evaluated the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

John Kuruvilla, MD, FRCPC, discusses the treatment landscape in relapsed/refractory Hodgkin lymphoma.

Jacob Sands, MD, discusses the FDA approval of lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.

Eric A. Klein, MD, discusses challenges with active surveillance in prostate cancer.

John P. Leonard, MD, discusses the FDA approval of tazemetostat in follicular lymphoma.

Caron Jacobson, MD, discusses the design of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Ronald Hoffman, MD, discusses the mechanism of action of the investigational hepcidin mimetic PTG-300 in polycythemia vera.

Sarah Rutherford, MD, discusses the importance of including patients with double-hit lymphoma in clinical trials.

Nilanjan Ghosh, MD, PhD, discusses the need to develop novel therapies in diffuse large B-cell lymphoma.

Aaron E. Katz, MD, FACS, discusses the Oncotype DX Genomic Prostate Score assay in patients with prostate cancer.

Mark M. Awad, MD, PhD, discusses the main objectives of the phase 2 GEOMETRY mono-1 study in patients with MET exon 14 skipping (METex14)-mutated non–small cell lung cancer (NSCLC).